Buy Jupiter Life Line Hospitals Ltd for the Target Rs.1,645 by Choice Institutional Equities
Key Conference Call Highlights
Operational Updates
* Operationalised the Dombivli hospital in February 2026, ahead of the originally scheduled Q1FY27 timeline, with early traction and encouraging patient response
* The management indicated that accreditation processes and insurance empanelment for the Dombivli hospital are under way, which should aid ramp up in the next few quarters.
* Existing hospitals continued to perform steadily, with Thane operating at ~75% occupancy, Pune at ~65% and Indore at 45–50% occupancy in FY26.
* ARPOB growth in FY26 was driven by improving case mix, maturity in the Indore facility and renewal of insurance contracts after nearly two years, leading to better pricing
* EBITDA in FY26 was impacted by the initial ramp-up losses from the Dombivli hospital, while depreciation and finance cost also increased due to ongoing capex and commercialisation of new assets
* The company is not materially reliant on international medical tourism; the business primarily caters to local residential catchments and domestic patients
* 25% of the BKC project land payment was completed in FY26 and the remaining payment expected in FY27E.
Expansion Pipeline
* Targeting a large post-IPO expansion pipeline of ~1,700 additional beds at an average cost of ~INR 1.5 Cr per bed, including projects at Dombivli, Pune South, Mira-Bhayandar and BKC.
* Further bed addition at the Indore facility would likely be initiated once occupancy crosses the ~60% threshold
* The Pune South hospital project remains on schedule, with the management indicating expected commissioning around the end of CY2028
* With BKC in pipeline, total expansion cycle ~1,700 new beds, taking long-term capacity to nearly 3,000 beds.
* BKC Project: The company has paid 25% of the land cost in accordance with the tender conditions; remainder to be paid in FY27. Project is still in regulatory clearance / pre-possession formalities with MMRDA; detailed capex numbers deferred until scope is finalised.
* Indore EBITDA/revenue ramp described as driven mainly by absorption of new beds added last year
* Expansion to be funded by internal accruals over ~4–5 years + debt, with a self-imposed ceiling of <3x EBITDA
Outlook
* The company continues to follow an asset-heavy expansion strategy by planned choice, focusing on owning and building largeformat hospitals in key micro-markets
* Dombivli hospital is anticipated to break even EBITDA within two years of operations
* Growth drivers would vary by hospital; Thane is driven largely by inflation-linked pricing growth, Pune, by higher occupancy as well as pricing growth and Indore, by occupancy ramp-up, improving case mix and pricing growth.
For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer
SEBI Registration no.: INZ 000160131
